Citation 143571

DAELS-RAKOTOARISON,DA: SEIDEL,V: GRESSIER,B: BRUNET,C: TILLEQUIN,F: BAILLEUL,F: LUYCKX,M: DINE,T: CAZIN,M: CAZIN,JC:. (2000). NEUROSEDATIVE AND ANTIOXIDANT ACTIVITIES OF PHENYLPROPANOIDS FROM BALLOTA NIGRA.. 50(1)

Citation Details

Title	NEUROSEDATIVE AND ANTIOXIDANT ACTIVITIES OF PHENYLPROPANOIDS FROM BALLOTA NIGRA.
Authors	DAELS-RAKOTOARISON,DA: SEIDEL,V: GRESSIER,B: BRUNET,C: TILLEQUIN,F: BAILLEUL,F: LUYCKX,M: DINE,T: CAZIN,M: CAZIN,JC:
Year	2000
Volume	50
Issue	1

Summary

Year: 2000

Journal: Unknown

Organisms and Their Experiments (1)

Ballota nigra (LAMIACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	VOUCHER SPECIMEN REPORTED FORISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	CAFFEOYL-L-MALIC ACID	None
2	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
3	RECEPTOR BINDING(DOPAMINE) DECREASED	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
4	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
5	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	WEAK ACTIVITY
6	HYDROGEN PEROXIDE SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
7	HYPOCHLOROUS ACID SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
8	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
9	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	INACTIVE
10	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
11	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	INACTIVE
12	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
13	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
14	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CAFFEOYL-L-MALIC ACID	ACTIVE
15	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	VERBASCOSIDE	None
16	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
17	RECEPTOR BINDING(DOPAMINE) DECREASED	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
18	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
19	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
20	HYDROGEN PEROXIDE SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
21	HYPOCHLOROUS ACID SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
22	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
23	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	INACTIVE
24	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
25	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	WEAK ACTIVITY
26	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
27	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
28	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	VERBASCOSIDE	ACTIVE
29	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	FORSYTHOSIDE B	None
30	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
31	RECEPTOR BINDING(DOPAMINE) DECREASED	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
32	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
33	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
34	HYDROGEN PEROXIDE SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
35	HYPOCHLOROUS ACID SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
36	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
37	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	INACTIVE
38	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
39	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	WEAK ACTIVITY
40	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
41	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
42	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	FORSYTHOSIDE B	ACTIVE
43	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	ARENARIOSIDE	None
44	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
45	RECEPTOR BINDING(DOPAMINE) DECREASED	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
46	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
47	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	WEAK ACTIVITY
48	HYDROGEN PEROXIDE SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
49	HYPOCHLOROUS ACID SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
50	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
51	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	INACTIVE
52	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	WEAK ACTIVITY
53	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
54	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
55	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
56	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	ARENARIOSIDE	ACTIVE
57	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	BALLOTETROSIDE	None
58	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
59	RECEPTOR BINDING(DOPAMINE) DECREASED	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
60	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
61	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
62	HYDROGEN PEROXIDE SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	ACTIVE
63	HYPOCHLOROUS ACID SCAVENGER ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	ACTIVE
64	SUPEROXIDE SCAVENGING ACTIVITY INCREASE	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
65	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
66	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	WEAK ACTIVITY
67	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE
68	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	ACTIVE
69	HYDROGEN PEROXIDE RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	ACTIVE
70	SUPEROXIDE PRODUCTION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BALLOTETROSIDE	INACTIVE

Citation 143571

Citation Details

Summary

Organisms and Their Experiments (1)

Ballota nigra (LAMIACEAE)

Show SPARQL Queries (1)

Query 1